Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases

Neuropathology

Volumn 33, Issue 6, 2013, Pages 612-620

  Niimi, Naoko ^a   Kohyama, Kuniko ^a   Matsumoto, Yoh ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Experimental autoimmune encephalomyelitis; Matrix metalloproteinases; Minocycline; siRNA; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

GELATINASE; GELATINASE A; GELATINASE B; MESSENGER RNA; MINOCYCLINE; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD; ZYMOGRAPHY;

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MATRIX METALLOPROTEINASES; MINOCYCLINE; SIRNA; TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; GELATINASES; MATRIX METALLOPROTEINASES; MINOCYCLINE; RATS; RATS, INBRED LEW; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SPINAL CORD; TISSUE INHIBITOR OF METALLOPROTEINASES; UP-REGULATION;

EID: 84897066284     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12039     Document Type: Article

References (19)

1. El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 2010; 5: 189-197.
2. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1991; 1: 97-105.
3. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254-260.
4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
5. Cossins JA, Clements JM, Ford J etal. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berl) 1997; 94: 590-598.
6. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-498.
7. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010; 67: 1442-1448.
8. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-223.
9. Nikodemova M, Lee J, Fabry Z, Duncan ID. Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord. J Neuroimmunol 2010; 219: 33-37.
10. Zhang Y, Metz LM, Yong VW etal. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008; 35: 185-191.
11. Oh LY, Larsen PH, Krekoski CA etal. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 1999; 19: 8464-8475.
12. Niimi N, Kohyama K, Matsumoto Y. Therapeutic gene silencing with siRNA for IL-23 but not for IL-17 suppresses the development of experimental autoimmune encephalomyelitis in rats. J Neuroimmunol 2013; 254: 39-45.
13. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-1308.
14. Maier K, Merkler D, Gerber J etal. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 2007; 25: 514-525.
15. Rosenberg GA. Matrix metalloproteinases biomarkers in multiple sclerosis. Lancet 2005; 365: 1291-1293.
16. Zabad RK, Metz LM, Todoruk TR etal. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13: 517-526.
17. Hu W, Metselaar J, Ben LH etal. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS ONE 2009; 4: e4151.
18. Hollborn M, Wiedemann P, Bringmann A, Kohen L. Chemotactic and cytotoxic effects of minocycline on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010; 51: 2721-2729.
19. Suzuki H, Sugimura Y, Iwama S etal. Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia. J Am Soc Nephrol 2010; 21: 2090-2098.